Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD

Blood (2007) 110 (11): 3107.

https://doi.org/10.1182/blood.V110.11.3107.3107

Published: 2007

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Margaret S. Lucas, PA-C, Nyla A. Heerema, PhD, Jennifer J. Matkovich, BS, Mollie E. Moran, CNP, Carolyn Cheney, BS, David M. Lucas, PhD, Donn C. Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2841.

https://doi.org/10.1182/blood.V108.11.2841.2841

Published: 2006

Journal Articles

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Thomas S. Lin, MD, PhD, Mitch Phelps, PhD, James T. Dalton, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Dimitrios Colevas, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2845.

https://doi.org/10.1182/blood.V108.11.2845.2845

Published: 2006

Journal Articles

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Gerard Lozanski, MD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 302.

https://doi.org/10.1182/blood.V108.11.302.302

Published: 2006

NARROW

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Email alerts

ASH Publications

American Society of Hematology

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only